Novo Nordisk
NVO
S$90.41
Share price
1.45%
Change (1 day)
-53.09%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Market capitalization of Novo Nordisk (NVO)
Market cap: S$400.07 Billion
As of June 2025 Novo Nordisk has a market cap of S$400.07 Billion. This makes Novo Nordisk the world's 32th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Novo Nordisk from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | S$400.07 B | -23.36% |
| 2024 | S$522.03 B | -85.51% |
| 2023 | S$3.602 T | 51.4% |
| 2022 | S$2.379 T | 589.94% |
| 2021 | S$344.83 B | 59.84% |
| 2020 | S$215.73 B | 15.02% |
| 2019 | S$187.56 B | 22.79% |
| 2018 | S$152.74 B | -85.09% |
| 2017 | S$1.024 T | 40.29% |
| 2016 | S$730.27 B | 238.98% |
| 2015 | S$215.43 B | 44.77% |
| 2014 | S$148.81 B | 16.08% |
| 2013 | S$128.20 B | 15.25% |
| 2012 | S$111.24 B | -78.53% |
| 2011 | S$518.10 B | 495.51% |
| 2010 | S$87.00 B | 53.09% |
| 2009 | S$56.83 B | 21.97% |
| 2008 | S$46.59 B | -22.84% |
| 2007 | S$60.38 B | -70.74% |
| 2006 | S$206.34 B | 46.08% |
| 2005 | S$141.25 B | 380.49% |
| 2004 | S$29.39 B | 22.34% |
| 2003 | S$24.02 B | -99.97% |
| 2002 | S$90.053 T | 4819.77% |
| 2001 | S$1.830 T | 29.25% |
| 2000 | S$1.416 T | 51.2% |
| 1999 | S$936.68 B | -14.36% |
| 1998 | S$1.093 T | -22.6% |
| 1997 | S$1.413 T | 73.86% |
| 1996 | S$812.74 B |
End of Day market cap according to different sources
On Jun 24th, 2025 the market cap of Novo Nordisk was reported to be:
S$403.70 Billion
S$400.32 Billion
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | S$176.67 B | -55.84% | 🇺🇸 USA |
 Eli Lilly LLY | S$892.91 B | 123.19% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | S$122.34 B | -69.42% | 🇺🇸 USA |
 Sanofi SNY | S$150.72 B | -62.33% | 🇫🇷 France |